Development of isotopically labelled 65Cu embedded PMMA-65CuO nanocomposites for detection and quantification of PMMA bone cement degradation at trace levels

Abstract

Polymethyl methacrylate (PMMA) bone cement is a popular bone-filling material for biomedical applications. Bone-cement implant failure is a common occurrence, but the consequence of this failure can be prevented/minimised by early detection of degradation. This work utilises a stable isotope labelling approach to monitor PMMA bone cement degradation. Stable isotopically enriched traceable nanoparticles of 65CuO were synthesized and introduced to PMMA bone cement. Accelerated and normal degradation of 65CuO-loaded PMMA bone cement nanocomposite was performed in acetone and simulated body fluid (SBF). 65Cu was detected and quantified upon PMMA bone cement nanocomposite degradation. The results showed a linear correlation between bone cement degradation and tracer release. When the 65CuO-PMMA composite deteriorated by 6.10 ± 3.04% in acetone, 5.6 ± 2.5 µg of tracer was released in 10 min. Similarly, after one week of degradation in SBF, 0.35 ± 0.31 µg of 65Cu tracer was released, translating to a 0.18 ± 0.09% weight loss. The stable isotopic tracer approach allowed us to measure and detect 65Cu under conditions of high background Cu concentration present in the human body upon 0.2% of PMMA nanocomposite degradation. 65CuO nanoparticles addition to PMMA bone cement did not alter the cytocompatibility (proliferation, differentiation, and osteocalcin formation) in MG-63 cells.